No #scandal here, say rare disease #drugmakers, as #pricing scrutiny lands on their doorstep
by Carly Helfand | May 19, 2017 Rare disease drugmakers, which have historically been better able to justify high prices than their peers, have recently ended up in the hot seat. Rare disease drugmakers get that their typically high prices are under the lens these days—just like everyone else’s. But they don’t all necessarily agree [...]